Phase 2: Number of Participants With 5-Level European Quality of Life-5 Dimensions (EQ-5D-5L): Health Utility Index Scale
A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3) · Source last updated 2024-11-19
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Baseline, Day 28, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, and Month 24
What was measured
The EQ-5D-5 levels(EQ-5D-5L)is a standardized measure of health status of the participant that provides a simple, generic measure of health for clinical and economic appraisal.It is a self-reported questionnaire used to assess the overall health status of participant scoring 5 dimensions of health: mobility,self-care,usual activities,pain/discomfort and anxiety/depression.Each dimension has 5 levels:no problems,slight problems,moderate problems,severe problems,and extreme problems.EQ-5D health states, defined by the EQ-5D descriptive system, are converted into a single summary index by a formula that attaches values (called QOL utilities)to each of the levels in each dimension.EQ-5D Summary Index values range from -0.11(worst health) to 1.00(perfect health).This decision results in a 1-digit number that shows the level for that dimension. The digits for 5 dimensions can be combined to 5-digit number that show the participant's health.Higher scores of EQ-5D-5L indicate better health.
Analysis population: Participants in Safety Analysis Set with available data were analyzed.
Groups in this outcome
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
Participants with r/r B-ALL received conditioning chemotherapy (fludarabine 25 mg/m\^2 IV over 30 minutes on Day -4, Day -3, and Day -2 and cyclophosphamide 900 mg/m\^2 IV over 60 minutes on Day -2) followed by a single infusion of brexucabtagene autoleucel CAR transduced autologous T cells administered IV at a target dose of 1 x 10\^6 anti-CD19 CAR T cells/kg of body weight on Day 0. For participants weighing \> 100 kg, a maximum flat dose of 1 x 10\^8 anti-CD19 CAR T cells/kg of body weight was administered.
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
51
Reported measurements
Baseline: Mobility (No problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
51
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
39
Not reported
Not reported
Not reported
Not reported
Baseline: Mobility (Slight problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
51
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
7
Not reported
Not reported
Not reported
Not reported
Baseline: Mobility (Moderate problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
51
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
4
Not reported
Not reported
Not reported
Not reported
Baseline: Mobility (Severe problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
51
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
1
Not reported
Not reported
Not reported
Not reported
Baseline: Mobility (Unable to walk)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
51
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Day 28: Mobility (No problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
42
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
19
Not reported
Not reported
Not reported
Not reported
Day 28: Mobility (Slight problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
42
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
10
Not reported
Not reported
Not reported
Not reported
Day 28: Mobility (Moderate problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
42
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
9
Not reported
Not reported
Not reported
Not reported
Day 28: Mobility (Severe problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
42
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
1
Not reported
Not reported
Not reported
Not reported
Day 28: Mobility (Unable to walk)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
42
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
3
Not reported
Not reported
Not reported
Not reported
Month 3: Mobility (No problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
26
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
19
Not reported
Not reported
Not reported
Not reported
Month 3: Mobility (Slight problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
26
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
5
Not reported
Not reported
Not reported
Not reported
Month 3: Mobility (Moderate problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
26
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
1
Not reported
Not reported
Not reported
Not reported
Month 3: Mobility (Severe problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
26
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 3: Mobility (Unable to walk)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
26
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
1
Not reported
Not reported
Not reported
Not reported
Month 6: Mobility (No problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
25
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
16
Not reported
Not reported
Not reported
Not reported
Month 6: Mobility (Slight problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
25
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
6
Not reported
Not reported
Not reported
Not reported
Month 6: Mobility (Moderate problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
25
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
2
Not reported
Not reported
Not reported
Not reported
Month 6: Mobility (Severe problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
25
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 6: Mobility (Unable to walk)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
25
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
1
Not reported
Not reported
Not reported
Not reported
Month 9: Mobility (No problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
10
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
8
Not reported
Not reported
Not reported
Not reported
Month 9: Mobility (Slight problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
10
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
1
Not reported
Not reported
Not reported
Not reported
Month 9: Mobility (Moderate problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
10
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 9: Mobility (Severe problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
10
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 9: Mobility (Unable to walk)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
10
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
1
Not reported
Not reported
Not reported
Not reported
Month 12: Mobility (No problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
14
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
11
Not reported
Not reported
Not reported
Not reported
Month 12: Mobility (Slight problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
14
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
3
Not reported
Not reported
Not reported
Not reported
Month 12: Mobility (Moderate problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
14
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 12: Mobility (Severe problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
14
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 12: Mobility (Unable to walk)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
14
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 15: Mobility (No problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
10
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
7
Not reported
Not reported
Not reported
Not reported
Month 15: Mobility (Slight problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
10
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
2
Not reported
Not reported
Not reported
Not reported
Month 15: Mobility (Moderate problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
10
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
1
Not reported
Not reported
Not reported
Not reported
Month 15: Mobility (Severity problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
10
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 15: Mobility (Unable to walk)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
10
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 18: Mobility (No problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
4
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
3
Not reported
Not reported
Not reported
Not reported
Month 18: Mobility (Slight problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
4
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
1
Not reported
Not reported
Not reported
Not reported
Month 18: Mobility (Moderate problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
4
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 18: Mobility (Severe problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
4
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 18: Mobility (Unable to walk)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
4
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 24: Mobility (No problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
4
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
3
Not reported
Not reported
Not reported
Not reported
Month 24: Mobility (Slight problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
4
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
1
Not reported
Not reported
Not reported
Not reported
Month 24: Mobility (Moderate problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
4
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 24: Mobility (Severe problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
4
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 24: Mobility (Unable to Walk)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
4
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Baseline: Self-care (No problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
51
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
44
Not reported
Not reported
Not reported
Not reported
Baseline: Self-care (Slight problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
51
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
5
Not reported
Not reported
Not reported
Not reported
Baseline: Self-care (Moderate problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
51
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
1
Not reported
Not reported
Not reported
Not reported
Baseline: Self-care (Severe problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
51
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
1
Not reported
Not reported
Not reported
Not reported
Baseline: Self-care (Unable to wash or dress)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
51
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Day 28: Self-care (No problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
42
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
31
Not reported
Not reported
Not reported
Not reported
Day 28: Self-care (Slight problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
42
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
6
Not reported
Not reported
Not reported
Not reported
Day 28: Self-care (Moderate problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
42
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
1
Not reported
Not reported
Not reported
Not reported
Day 28: Self-care (Severe problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
42
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
2
Not reported
Not reported
Not reported
Not reported
Day 28: Self-care (Unable to wash or dress)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
42
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
2
Not reported
Not reported
Not reported
Not reported
Month 3: Self-care (No problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
25
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
23
Not reported
Not reported
Not reported
Not reported
Month 3: Self-care (Slight problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
25
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
1
Not reported
Not reported
Not reported
Not reported
Month 3: Self-care (Moderate problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
25
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
1
Not reported
Not reported
Not reported
Not reported
Month 3: Self-care (Severe problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
25
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 3: Self-care (Unable to wash or dress)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
25
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 6: Self-care (No problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
25
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
23
Not reported
Not reported
Not reported
Not reported
Month 6: Self-care (Slight problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
51
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 6: Self-care (Moderate problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
51
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
1
Not reported
Not reported
Not reported
Not reported
Month 6: Self-care (Severe problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
51
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
1
Not reported
Not reported
Not reported
Not reported
Month 6: Self-care (Unable to wash or dress)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
10
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 9: Self-care (No problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
10
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
9
Not reported
Not reported
Not reported
Not reported
Month 9: Self-care (Slight problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
10
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 9: Self-care (Moderate problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
10
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 9: Self-care (Severe problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
10
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
1
Not reported
Not reported
Not reported
Not reported
Month 9: Self-care (Unable to wash or dress)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
51
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 12: Self-care (No problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
14
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
14
Not reported
Not reported
Not reported
Not reported
Month 12: Self-care (Slight problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
14
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 12: Self-care (Moderate problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
14
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 12: Self-care (Severe problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
14
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 12: Self-care (Unable to wash or dress)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
14
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 15: Self-care (No problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
10
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
10
Not reported
Not reported
Not reported
Not reported
Month 15: Self-care (Slight problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
10
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 15: Self-care (Moderate problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
10
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 15: Self-care (Severe problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
10
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 15: Self-care (Unable to wash or dress)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
10
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 18: Self-care (No problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
4
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
4
Not reported
Not reported
Not reported
Not reported
Month 18: Self-care (Slight problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
4
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 18: Self-care (Moderate problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
4
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 18: Self-care (Severe problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
4
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 18: Self-care (Unable to wash or dress)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
4
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 24: Self-care (No problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
4
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
4
Not reported
Not reported
Not reported
Not reported
Month 24: Self-care (Slight problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
4
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 24: Self-care (Moderate problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
4
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 24: Self-care (Severe problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
4
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 24: Self-care (Unable to wash or dress)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
4
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Baseline: Usual activities (No problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
51
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
24
Not reported
Not reported
Not reported
Not reported
Baseline: Usual activities (Slight problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
51
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
14
Not reported
Not reported
Not reported
Not reported
Baseline: Usual activities (Moderate problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
51
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
9
Not reported
Not reported
Not reported
Not reported
Baseline: Usual activities (Severe problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
51
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
3
Not reported
Not reported
Not reported
Not reported
Baseline: Usual activities (Unable to do usual activities)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
51
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
1
Not reported
Not reported
Not reported
Not reported
Day 28: Usual activities (No problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
42
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
17
Not reported
Not reported
Not reported
Not reported
Day 28: Usual activities (Slight problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
42
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
13
Not reported
Not reported
Not reported
Not reported
Day 28: Usual activities (Moderate problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
42
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
8
Not reported
Not reported
Not reported
Not reported
Day 28: Usual activities (Severe problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
42
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
3
Not reported
Not reported
Not reported
Not reported
Day 28: Usual activities (Unable to do usual activities)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
42
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
1
Not reported
Not reported
Not reported
Not reported
Month 3: Usual activities (No problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
25
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
14
Not reported
Not reported
Not reported
Not reported
Month 3: Usual activities (Slight problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
25
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
9
Not reported
Not reported
Not reported
Not reported
Month 3: Usual activities (Moderate problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
25
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
1
Not reported
Not reported
Not reported
Not reported
Month 3: Usual activities (Severe problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
25
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
1
Not reported
Not reported
Not reported
Not reported
Month 3: Usual activities (Unable to do usual activities)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
25
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 6: Usual activities (No problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
25
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
17
Not reported
Not reported
Not reported
Not reported
Month 6: Usual activities (Slight problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
25
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
4
Not reported
Not reported
Not reported
Not reported
Month 6: Usual activities (Moderate problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
25
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
2
Not reported
Not reported
Not reported
Not reported
Month 6: Usual activities (Severe problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
25
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
2
Not reported
Not reported
Not reported
Not reported
Month 6: Usual activities (Unable to do usual activities)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
25
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 9: Usual activities (No problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
10
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
9
Not reported
Not reported
Not reported
Not reported
Month 9: Usual activities (Slight problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
10
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 9: Usual activities (Moderate problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
10
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 9: Usual activities (Severe problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
10
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 9: Usual activities (Unable to do usual activities)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
10
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
1
Not reported
Not reported
Not reported
Not reported
Month 12: Usual activities (No problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
14
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
11
Not reported
Not reported
Not reported
Not reported
Month 12: Usual activities (Slight problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
14
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
3
Not reported
Not reported
Not reported
Not reported
Month 12: Usual activities (Moderate problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
14
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 12: Usual activities (Severe problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
14
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 12: Usual activities (Unable to do usual activities)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
14
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 15: Usual activities (No problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
10
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
8
Not reported
Not reported
Not reported
Not reported
Month 15: Usual activities (Slight problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
10
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
2
Not reported
Not reported
Not reported
Not reported
Month 15: Usual activities (Moderate problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
10
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 15: Usual activities (Severe problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
10
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 15: Usual activities (Unable to do usual activities)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
10
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 18: Usual activities (No problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
4
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
1
Not reported
Not reported
Not reported
Not reported
Month 18: Usual activities (Slight problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
4
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
3
Not reported
Not reported
Not reported
Not reported
Month 18: Usual activities (Moderate problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
4
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 18: Usual activities (Severe problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
4
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 18: Usual activities (Unable to do usual activities)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
4
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 24: Usual activities (No problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
4
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
4
Not reported
Not reported
Not reported
Not reported
Month 24: Usual activities (Slight problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
4
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 24: Usual activities (Moderate problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
4
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 24: Usual activities (Severe problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
4
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 24: Usual activities (Unable to do usual activities)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
4
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Baseline: Pain/Discomfort (No Problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
51
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
23
Not reported
Not reported
Not reported
Not reported
Baseline: Pain/Discomfort (Slight Problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
51
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
16
Not reported
Not reported
Not reported
Not reported
Baseline: Pain/Discomfort (Moderate Problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
51
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
12
Not reported
Not reported
Not reported
Not reported
Baseline: Pain/Discomfort (Severe Problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
51
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Baseline: Pain/Discomfort (Extreme Pain or discomfort)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
51
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Day 28: Pain/Discomfort (No Problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
42
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
19
Not reported
Not reported
Not reported
Not reported
Day 28: Pain/Discomfort (Slight Problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
42
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
14
Not reported
Not reported
Not reported
Not reported
Day 28: Pain/Discomfort (Moderate Problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
42
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
9
Not reported
Not reported
Not reported
Not reported
Day 28: Pain/Discomfort (Severe Problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
42
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Day 28: Pain/Discomfort (Extreme Pain or discomfort)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
42
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 3: Pain/Discomfort (No Problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
26
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
11
Not reported
Not reported
Not reported
Not reported
Month 3: Pain/Discomfort (Slight Problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
26
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
9
Not reported
Not reported
Not reported
Not reported
Month 3: Pain/Discomfort (Moderate Problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
26
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
6
Not reported
Not reported
Not reported
Not reported
Month 3: Pain/Discomfort (Severe Problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
26
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 3: Pain/Discomfort (Extreme Pain or discomfort)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
26
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 6: Pain/Discomfort (No Problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
25
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
11
Not reported
Not reported
Not reported
Not reported
Month 6: Pain/Discomfort (Slight Problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
25
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
5
Not reported
Not reported
Not reported
Not reported
Month 6: Pain/Discomfort (Moderate Problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
25
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
7
Not reported
Not reported
Not reported
Not reported
Month 6: Pain/Discomfort (Severe Problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
25
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
2
Not reported
Not reported
Not reported
Not reported
Month 6: Pain/Discomfort (Extreme Pain or discomfort)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
25
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 9: Pain/Discomfort (No Problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
10
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
7
Not reported
Not reported
Not reported
Not reported
Month 9: Pain/Discomfort (Slight Problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
10
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
1
Not reported
Not reported
Not reported
Not reported
Month 9: Pain/Discomfort (Moderate Problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
10
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
2
Not reported
Not reported
Not reported
Not reported
Month 9: Pain/Discomfort (Severe Problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
10
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 9: Pain/Discomfort (Extreme Pain or discomfort)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
10
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 12: Pain/Discomfort (No Problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
14
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
7
Not reported
Not reported
Not reported
Not reported
Month 12: Pain/Discomfort (Slight Problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
14
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
6
Not reported
Not reported
Not reported
Not reported
Month 12: Pain/Discomfort (Moderate Problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
14
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
1
Not reported
Not reported
Not reported
Not reported
Month 12: Pain/Discomfort (Severe Problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
14
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 12: Pain/Discomfort (Extreme Pain or discomfort)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
14
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 15: Pain/Discomfort (No Problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
10
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
6
Not reported
Not reported
Not reported
Not reported
Month 15: Pain/Discomfort (Slight Problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
10
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
4
Not reported
Not reported
Not reported
Not reported
Month 15: Pain/Discomfort (Moderate Problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
10
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 15: Pain/Discomfort (Severe Problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
10
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 15: Pain/Discomfort (Extreme Pain or discomfort)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
10
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 18: Pain/Discomfort (No Problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
4
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
1
Not reported
Not reported
Not reported
Not reported
Month 18: Pain/Discomfort (Slight Problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
4
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
3
Not reported
Not reported
Not reported
Not reported
Month 18: Pain/Discomfort (Moderate Problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
4
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 18: Pain/Discomfort (Severe Problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
4
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 18: Pain/Discomfort (Extreme Pain or discomfort)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
4
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 24: Pain/Discomfort (No Problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
4
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
3
Not reported
Not reported
Not reported
Not reported
Month 24: Pain/Discomfort (Slight Problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
4
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
1
Not reported
Not reported
Not reported
Not reported
Month 24: Pain/Discomfort (Moderate Problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
4
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 24: Pain/Discomfort (Severe Problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
4
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 24: Pain/Discomfort (Extreme Pain or discomfort)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
4
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Baseline: Anxiety/Depression (No problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
51
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
30
Not reported
Not reported
Not reported
Not reported
Baseline: Anxiety/Depression (Slight problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
51
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
12
Not reported
Not reported
Not reported
Not reported
Baseline: Anxiety/Depression (Moderate problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
51
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
7
Not reported
Not reported
Not reported
Not reported
Baseline: Anxiety/Depression (Severe problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
51
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
2
Not reported
Not reported
Not reported
Not reported
Baseline: Anxiety/Depression (Extreme Anxious or Depressed)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
51
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Day 28: Anxiety/Depression (No problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
42
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
28
Not reported
Not reported
Not reported
Not reported
Day 28: Anxiety/Depression (Slight problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
42
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
11
Not reported
Not reported
Not reported
Not reported
Day 28: Anxiety/Depression (Moderate problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
42
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
3
Not reported
Not reported
Not reported
Not reported
Day 28: Anxiety/Depression (Severe problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
42
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Day 28: Anxiety/Depression (Extreme Anxious or Depressed)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
42
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 3: Anxiety/Depression (No problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
26
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
17
Not reported
Not reported
Not reported
Not reported
Month 3: Anxiety/Depression (Slight problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
26
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
6
Not reported
Not reported
Not reported
Not reported
Month 3: Anxiety/Depression (Moderate problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
26
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
3
Not reported
Not reported
Not reported
Not reported
Month 3: Anxiety/Depression (Severe problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
26
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 3: Anxiety/Depression (Extreme Anxious or Depressed)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
26
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 6: Anxiety/Depression (No problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
25
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
18
Not reported
Not reported
Not reported
Not reported
Month 6: Anxiety/Depression (Slight problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
25
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
4
Not reported
Not reported
Not reported
Not reported
Month 6: Anxiety/Depression (Moderate problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
25
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
3
Not reported
Not reported
Not reported
Not reported
Month 6: Anxiety/Depression (Severe problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
25
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 6: Anxiety/Depression (Extreme Anxious or Depressed)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
25
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 9: Anxiety/Depression (No problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
10
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
9
Not reported
Not reported
Not reported
Not reported
Month 9: Anxiety/Depression (Slight problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
10
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 9: Anxiety/Depression (Moderate problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
10
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
1
Not reported
Not reported
Not reported
Not reported
Month 9: Anxiety/Depression (Severe problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
10
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 9: Anxiety/Depression (Extreme Anxious or Depressed)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
10
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 12: Anxiety/Depression (No problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
14
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
10
Not reported
Not reported
Not reported
Not reported
Month 12: Anxiety/Depression (Slight problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
14
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
2
Not reported
Not reported
Not reported
Not reported
Month 12: Anxiety/Depression (Moderate problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
14
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
2
Not reported
Not reported
Not reported
Not reported
Month 12: Anxiety/Depression (Severe problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
14
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 12: Anxiety/Depression (Extreme Anxious or Depressed)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
14
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 15: Anxiety/Depression (No problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
10
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
7
Not reported
Not reported
Not reported
Not reported
Month 15: Anxiety/Depression (Slight problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
10
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
2
Not reported
Not reported
Not reported
Not reported
Month 15: Anxiety/Depression (Moderate problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
10
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
1
Not reported
Not reported
Not reported
Not reported
Month 15: Anxiety/Depression (Severe problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
10
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 15: Anxiety/Depression (Extreme Anxious or Depressed)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
10
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 18: Anxiety/Depression (No problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
4
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
3
Not reported
Not reported
Not reported
Not reported
Month 18: Anxiety/Depression (Slight problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
4
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
1
Not reported
Not reported
Not reported
Not reported
Month 18: Anxiety/Depression (Moderate problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
4
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 18: Anxiety/Depression (Severe problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
4
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 18: Anxiety/Depression (Extreme Anxious or Depressed)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
4
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 24: Anxiety/Depression (No problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
4
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
4
Not reported
Not reported
Not reported
Not reported
Month 24: Anxiety/Depression (Slight problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
4
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 24: Anxiety/Depression (Moderate problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
4
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 24: Anxiety/Depression (Severe problem)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
4
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Month 24: Anxiety/Depression (Extreme Anxious or Depressed)
Analysis denominator · Participants
Group
Source count
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
4
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
0
Not reported
Not reported
Not reported
Not reported
Complete source fields
calculate Pct
false
classes
categories
measurements
group Id
OG000
value
39
denoms
counts
group Id
OG000
value
51
units
Participants
title
Baseline: Mobility (No problem)
categories
measurements
group Id
OG000
value
7
denoms
counts
group Id
OG000
value
51
units
Participants
title
Baseline: Mobility (Slight problem)
categories
measurements
group Id
OG000
value
4
denoms
counts
group Id
OG000
value
51
units
Participants
title
Baseline: Mobility (Moderate problem)
categories
measurements
group Id
OG000
value
1
denoms
counts
group Id
OG000
value
51
units
Participants
title
Baseline: Mobility (Severe problem)
categories
measurements
group Id
OG000
value
0
denoms
counts
group Id
OG000
value
51
units
Participants
title
Baseline: Mobility (Unable to walk)
categories
measurements
group Id
OG000
value
19
denoms
counts
group Id
OG000
value
42
units
Participants
title
Day 28: Mobility (No problem)
categories
measurements
group Id
OG000
value
10
denoms
counts
group Id
OG000
value
42
units
Participants
title
Day 28: Mobility (Slight problem)
categories
measurements
group Id
OG000
value
9
denoms
counts
group Id
OG000
value
42
units
Participants
title
Day 28: Mobility (Moderate problem)
categories
measurements
group Id
OG000
value
1
denoms
counts
group Id
OG000
value
42
units
Participants
title
Day 28: Mobility (Severe problem)
categories
measurements
group Id
OG000
value
3
denoms
counts
group Id
OG000
value
42
units
Participants
title
Day 28: Mobility (Unable to walk)
categories
measurements
group Id
OG000
value
19
denoms
counts
group Id
OG000
value
26
units
Participants
title
Month 3: Mobility (No problem)
categories
measurements
group Id
OG000
value
5
denoms
counts
group Id
OG000
value
26
units
Participants
title
Month 3: Mobility (Slight problem)
denoms
counts
group Id
OG000
value
51
units
Participants
description
The EQ-5D-5 levels(EQ-5D-5L)is a standardized measure of health status of the participant that provides a simple, generic measure of health for clinical and economic appraisal.It is a self-reported questionnaire used to assess the overall health status of participant scoring 5 dimensions of health: mobility,self-care,usual activities,pain/discomfort and anxiety/depression.Each dimension has 5 levels:no problems,slight problems,moderate problems,severe problems,and extreme problems.EQ-5D health states, defined by the EQ-5D descriptive system, are converted into a single summary index by a formula that attaches values (called QOL utilities)to each of the levels in each dimension.EQ-5D Summary Index values range from -0.11(worst health) to 1.00(perfect health).This decision results in a 1-digit number that shows the level for that dimension. The digits for 5 dimensions can be combined to 5-digit number that show the participant's health.Higher scores of EQ-5D-5L indicate better health.
groups
description
Participants with r/r B-ALL received conditioning chemotherapy (fludarabine 25 mg/m\^2 IV over 30 minutes on Day -4, Day -3, and Day -2 and cyclophosphamide 900 mg/m\^2 IV over 60 minutes on Day -2) followed by a single infusion of brexucabtagene autoleucel CAR transduced autologous T cells administered IV at a target dose of 1 x 10\^6 anti-CD19 CAR T cells/kg of body weight on Day 0. For participants weighing \> 100 kg, a maximum flat dose of 1 x 10\^8 anti-CD19 CAR T cells/kg of body weight was administered.
id
OG000
title
Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg
param Type
COUNT_OF_PARTICIPANTS
population Description
Participants in Safety Analysis Set with available data were analyzed.
reporting Status
POSTED
time Frame
Baseline, Day 28, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, and Month 24
title
Phase 2: Number of Participants With 5-Level European Quality of Life-5 Dimensions (EQ-5D-5L): Health Utility Index Scale
Triangle